Just eight days after the Supreme Court of the United States ruling granting vaccine manufacturers virtual immunity over prosecution ( Bruesewitz v. Wyeth) , scientists and company representatives met at a congress in Baltimore to “Understand the Changes in the National Vaccine Plan to Maximize Government Sponsored Funding and Avoid FDA Scrutiny”. The “workshop” which took place on 2 March 2011 was the first event in a Vaccine Business Congress held under the auspices of the Institute for International Research USA . Amongst the many participants at the congress were representatives of Merck, GlaxoSmithKline, Sanofi Pasteur, Roche, the Bill and Melinda Gates Foundation, the Wellcome Trust, and the National Cancer Institute (NIH) (IIRUSA Welcome , IIRUSA Agenda ).
Despite frequent bleating from industry apologists that vaccine manufacturers do not make money the pre publicity for the event showed the industry in rampant mood. The on-line brochure states:
“VACCINES are the continuing success story, earning over $27 billion in 2009 alone, despite difficult economic times for the pharmaceutical industry. By 2012, vaccines are expected to bring in more than $35 billion in revenue.”